SKINPULSE PODCAST: Where skin meets science
Type 2 inflammation connects conditions that appear unrelated. Yet the connections are often missed. SKINPULSE exists to change that. Each episode brings together leading clinical experts to explore the systemic drivers behind what you see on the skin — translating complex science into insights that are relevant, accessible, and immediately applicable to your practice.
What to expect:
- Evidence-based discussions led by world-class KOLs
- Topics spanning dermatology, immunology, and type 2 inflammation
- Science that connects the dots across specialties and disease areas
Available on all major podcast platforms — listen between patients, on your commute, or whenever it suits you.
Subscribe to SKINPULSE and join the conversation that is reshaping how we understand type 2 inflammation.
THE LATEST EPISODE
SKINPULSE Episode 2 - Type 2 Inflammation: From Science to Screening with Prof. Palomares
Join us for an insightful conversation with Prof Palomares as we explore the fundamentals of type 2 inflammation and its clinical significance.
In this episode, we discuss the underlying mechanisms of the type 2 immune response, how it manifests in various conditions, and the practical challenges healthcare providers face in identifying patients with type 2-driven diseases. Prof. Palomares also shares details about screening tool designed to improve detection and patient outcomes.
Previous episodes
In this episode of SKINPULSE, world-renowned dermatologist Prof. Thomas Bieber explores disease-modifying approaches in atopic dermatitis management—moving beyond symptomatic treatment to address the underlying disease trajectory.
Prof. Bieber examines the disease modification concept, cumulative life course impairment, and the multidimensional burden of atopic dermatitis across pediatric and adult populations. He discusses the critical role of early intervention and the connection between skin barrier dysfunction and the atopic march, revealing how visible skin manifestations reflect deeper systemic type 2 inflammation.
